产品编号 :
Cas No. :
CAS No. |
2444764-03-6 |
|---|---|
中文名称 |
GKI-1(该名称为研发代号/缩写,非IUPAC系统命名;仅凭此无法生成符合CCS/IUPAC的无歧义中文系统名,需提供结构式(SMILES/InChI)或完整英文系统命名) |
英文名称 |
GKI-1 |
别名 |
Benzenamine, N-(4-chlorophenyl)-3-(1H-pyrazol-4-yl)-;GKI-1, 10 mM in DMSO |
标准英文名 |
N-(4-chlorophenyl)-3-(1H-pyrazol-4-yl)aniline |
MDL No. |
MFCD31813592 |
分子式 |
C15H12ClN3 |
分子量 |
269.73 |
精确分子量 |
269.07 |
SMILES |
ClC1=CC=C(NC2=CC(C3=CNN=C3)=CC=C2)C=C1 |
标准SMILES |
ClC1C=CC(=CC=1)NC1=CC(=CC=C1)C1=CNN=C1 |
用途 |
GKI-1 is a Greatwall (GWL) kinase inhibitor used to inhibit full-length human GWL (hGWLFL) and its kinase domain (hGWL-KinDom) with IC50 values of 4.9 µM and 2.5 µM, respectively; it also potently inhibits ROCK1 (IC50 = 11 µM) with minimal effect on PKA. It is applied in vitro to reduce ENSA/ARPP19 phosphorylation levels in HeLa cells, leading to decreased mitotic events, mitotic arrest, cell death, and cytokinesis failure. |
InChIKey |
GPXJDHFWTOJHQQ-UHFFFAOYSA-N |
|
|
评论 |
|---|